Literature DB >> 28539466

Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Jeho Jeong1, Jung Hun Oh2, Jan-Jakob Sonke3, Jose Belderbos3, Jeffrey D Bradley4, Andrew N Fontanella2, Shyam S Rao5, Joseph O Deasy1.   

Abstract

Purpose: To demonstrate that a mathematical model can be used to quantitatively understand tumor cellular dynamics during a course of radiotherapy and to predict the likelihood of local control as a function of dose and treatment fractions.Experimental Design: We model outcomes for early-stage, localized non-small cell lung cancer (NSCLC), by fitting a mechanistic, cellular dynamics-based tumor control probability that assumes a constant local supply of oxygen and glucose. In addition to standard radiobiological effects such as repair of sub-lethal damage and the impact of hypoxia, we also accounted for proliferation as well as radiosensitivity variability within the cell cycle. We applied the model to 36 published and two unpublished early-stage patient cohorts, totaling 2,701 patients.
Results: Precise likelihood best-fit values were derived for the radiobiological parameters: α [0.305 Gy-1; 95% confidence interval (CI), 0.120-0.365], the α/β ratio (2.80 Gy; 95% CI, 0.40-4.40), and the oxygen enhancement ratio (OER) value for intermediately hypoxic cells receiving glucose but not oxygen (1.70; 95% CI, 1.55-2.25). All fractionation groups are well fitted by a single dose-response curve with a high χ2 P value, indicating consistency with the fitted model. The analysis was further validated with an additional 23 patient cohorts (n = 1,628). The model indicates that hypofractionation regimens overcome hypoxia (and cell-cycle radiosensitivity variations) by the sheer impact of high doses per fraction, whereas lower dose-per-fraction regimens allow for reoxygenation and corresponding sensitization, but lose effectiveness for prolonged treatments due to proliferation.Conclusions: This proposed mechanistic tumor-response model can accurately predict overtreatment or undertreatment for various treatment regimens. Clin Cancer Res; 23(18); 5469-79. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28539466      PMCID: PMC5600831          DOI: 10.1158/1078-0432.CCR-16-3277

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  69 in total

1.  Mechanistic formulation of a lineal-quadratic-linear (LQL) model: split-dose experiments and exponentially decaying sources.

Authors:  Mariana Guerrero; Marco Carlone
Journal:  Med Phys       Date:  2010-08       Impact factor: 4.071

2.  The inactivation of Chinese hamster cells by x rays: synchronized and exponential cell populations.

Authors:  C J Gillespie; J D Chapman; A P Reuvers; D L Dugle
Journal:  Radiat Res       Date:  1975-11       Impact factor: 2.841

3.  The combined effects of sublethal damage repair, cellular repopulation and redistribution in the mitotic cycle. II. The dependency of radiosensitivity parameters alpha, beta and t(0) on biological age for Chinese hamster V79 cells.

Authors:  M Zaider
Journal:  Radiat Res       Date:  1996-04       Impact factor: 2.841

4.  Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al.

Authors:  Shyam S Rao; Jung Hun Oh; Andrew Jackson; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-01       Impact factor: 7.038

5.  Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.

Authors:  J Martin Brown; Maximilian Diehn; Billy W Loo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

Review 6.  Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS).

Authors:  Heon Joo Park; Robert J Griffin; Susanta Hui; Seymour H Levitt; Chang W Song
Journal:  Radiat Res       Date:  2012-01-09       Impact factor: 2.841

Review 7.  Tumor hypoxia as a modifier of DNA strand break and cross-link repair.

Authors:  Norman Chan; Cameron J Koch; Robert G Bristow
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Oxygen enhancement ratio as a function of dose and cell cycle phase for radiation-resistant and sensitive CHO cells.

Authors:  J P Freyer; K Jarrett; S Carpenter; M R Raju
Journal:  Radiat Res       Date:  1991-09       Impact factor: 2.841

9.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.

Authors:  Robert Timmerman; Lech Papiez; Ronald McGarry; Laura Likes; Colleen DesRosiers; Stephanie Frost; Mark Williams
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

10.  Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

Authors:  Norman Chan; Marianne Koritzinsky; Helen Zhao; Ranjit Bindra; Peter M Glazer; Simon Powell; Abdellah Belmaaza; Brad Wouters; Robert G Bristow
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

View more
  8 in total

1.  The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer.

Authors:  Jeho Jeong; Vicki T Taasti; Andrew Jackson; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2020-09-23       Impact factor: 6.280

Review 2.  Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Authors:  Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

3.  High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview.

Authors:  Jimm Grimm; Lawrence B Marks; Andrew Jackson; Brian D Kavanagh; Jinyu Xue; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-01       Impact factor: 8.013

Review 4.  Optimizing the future: how mathematical models inform treatment schedules for cancer.

Authors:  Deepti Mathur; Ethan Barnett; Howard I Scher; Joao B Xavier
Journal:  Trends Cancer       Date:  2022-03-09

5.  Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT.

Authors:  Pranshu Mohindra; Amit Sawant; Robert J Griffin; Narottam Lamichhane; Erina Vlashi; Meng Xu-Welliver; Michael Dominello; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-02-22       Impact factor: 2.102

6.  Re: Simulation analysis for tumor radiotherapy based on three-component mathematical models.

Authors:  Meghan C Ferrall-Fairbanks; Daniel J Glazar; Renee J Brady; Gregory J Kimmel; Mohammad U Zahid; Philipp M Altrock; Heiko Enderling
Journal:  J Appl Clin Med Phys       Date:  2019-05-30       Impact factor: 2.102

7.  Dose-Response Analysis Describes Particularly Rapid Repopulation of Non-Small Cell Lung Cancer during Concurrent Chemoradiotherapy.

Authors:  Huei-Tyng Huang; Michael G Nix; Douglas H Brand; David Cobben; Crispin T Hiley; John D Fenwick; Maria A Hawkins
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

8.  Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model.

Authors:  Changran Geng; Harald Paganetti; Clemens Grassberger
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.